Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CEP1347 |
Synonyms | |
Therapy Description |
CEP1347 inhibits PAK and MLK family kinases, which potentially induces differentiation and inhibits cancer stem cell self-renewal and tumor growth (PMID: 29212273, PMID: 12184411). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CEP1347 | CEP-1347|CEP 1347 | CEP1347 inhibits PAK and MLK family kinases, which potentially induces differentiation and inhibits cancer stem cell self-renewal and tumor growth (PMID: 29212273, PMID: 12184411). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 wild-type | meningioma | sensitive | CEP1347 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, CEP-1347 induced apoptosis, inhibited viability, and decreased colony formation in a TP53 wild-type meningioma cell line in culture and inhibited tumor growth in a cell line xenograft model (PMID: 37509605). | 37509605 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|